Where To Buy Peptides  ·  SS-31 · Basics

SS-31 benefits

SS-31: one benefit on the list has a drug label behind it. The rest is borrowed from mouse work, review articles, and a randomized trial that missed its primary endpoints.

WTBP Research Team Updated 2026-11-12 9 min read 13 cited sources

Search SS-31 benefits and you get a long list. The approved list has one item: muscle strength in Barth syndrome, in patients weighing 30 kg or more. The long-term safety record for that use comes from 8 people.

The short answer. SS-31 has one approved benefit: muscle strength in Barth syndrome, in patients of 30 kg or more.

SS-31 is elamipretide. The FDA approved it in September 2025. The one approved use is Barth syndrome. Long-term data covers 8 patients over 168 weeks. A larger myopathy trial missed both primary endpoints. Anti-aging claims rest on aged mice, not people.

What SS-31 is actually approved to do

SS-31 is elamipretide. It is a four-amino-acid peptide, sequence D-Arg-Dmt-Lys-Phe-NH₂. It is sold as Forzinity. The FDA cleared it in September 2025, and Shirley's 2025 Drugs first-approval summary records the same single indication: Barth syndrome, in patients weighing 30 kg or more.

Barth syndrome is an X-linked disorder of cardiolipin remodeling. Clarke and colleagues, writing in the Orphanet Journal of Rare Diseases in 2013, describe it as affecting roughly 1 in 300,000–400,000 male births. That is the population the approval covers.

The supporting trial was TAZPOWER. It ran 28 weeks randomized, then continued as an open-label extension reported out to 168 weeks in 8 patients in Genetics in Medicine. Eight is not a typo. It is the whole long-term dataset.

The approval is real, and it is narrow. It is a permission slip for one ultra-rare disease, not for mitochondrial health in general.

We break the regulatory record down on the SS-31 Barth syndrome FDA page, and the biochemistry on the cardiolipin mechanism page.

Each claimed benefit, traced to its source

Most benefit lists for this compound mix four different kinds of evidence into one bullet list. Separated out, they look like this.

Claimed benefitWhere it comes fromSpecies and status
Muscle strength in Barth syndromeTAZPOWER, 28-week randomized plus 168-week extensionHuman. FDA approved.
Exercise capacity in primary mitochondrial myopathyMMPOWER-3, Karaa et al., Neurology 2023Human. Missed primary endpoints.
Walking distance in one genotype subgroupPost hoc analysis, Orphanet Journal of Rare Diseases 2024Human. Exploratory only.
Heart failure benefitObi et al., Heart Failure Reviews 2022Review article. No approval.
Dry AMD and retinal protectionNashine, Cells 2021; Rowe et al., 2025Candidate lists and early work. No approval.
Duchenne cardiomyopathyGandhi et al., Cells 2024Review of mitochondrial therapeutics. Preclinical.
Anti-aging, longevity, "cellular age reversal"Mitchell et al., Aging Cell 2025Aged mice.
General energy, recovery, brain fogNothing publishedNone.

Tung and colleagues reviewed the structure, mechanism and therapeutic potential of elamipretide in the International Journal of Molecular Sciences in 2025. A review of potential is a map of where trials could go. It is not a record of trials that landed.

Does SS-31 slow aging?

The best aging study of this compound is a mouse study, and its own title is the answer.

The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age.

Mitchell et al., Aging Cell, 2025 (title)

Read that twice. Function improved. The molecular clocks did not move.

So the honest version of the longevity pitch is: a mitochondria-targeted peptide made old mouse muscle work better, while leaving the aging biomarkers where they were. That is interesting. It is not a human benefit, and zero randomized trials have tested SS-31 for aging in people.

What about heart failure, eyes and muscular dystrophy?

These three show up on every benefit list. All three are at the stage before proof.

Heart failure. Obi and colleagues published a 2022 review in Heart Failure Reviews on targeting mitochondrial dysfunction with elamipretide. Cardiolipin loss is a documented feature of failing myocardium, so the rationale is sound. The drug is not approved for heart failure, and no trial has made it one.

Eyes. Nashine's 2021 paper in Cells lists elamipretide among potential therapeutic candidates for age-related macular degeneration. Rowe and colleagues, writing in Expert Opinion on Pharmacotherapy in 2025, place mitochondrial agents inside a wider discussion of how retinal drugs get delivered at all. Candidate status is the correct description.

Duchenne. Gandhi and colleagues, in Cells in 2024, argue mitochondrial therapeutics could improve treatment response in Duchenne cardiomyopathy. That is a hypothesis paper about a class, not a result for this peptide.

A review saying a compound "has potential" in a disease is the opposite of a trial saying it worked. Benefit lists quietly convert one into the other.

The trial that did not work

The largest randomized test of SS-31 was MMPOWER-3, in primary mitochondrial myopathy. Karaa and colleagues reported it in Neurology in 2023.

Elamipretide did not meet the primary endpoints of change in six-minute walk test distance or total fatigue score at 24 weeks.

Karaa et al., MMPOWER-3, Neurology, 2023

That is a negative result at 24 weeks in the broad mitochondrial myopathy population. It matters, because the grey-market pitch for this peptide is mostly fatigue and exercise capacity, which is precisely what MMPOWER-3 measured and did not move.

A 2024 post hoc analysis in the Orphanet Journal of Rare Diseases split the trial by genotype and reported walk-distance differences in some subgroups, with figures including 25.2 m versus 2.0 m. Post hoc subgroup findings generate hypotheses. They do not rescue a missed endpoint. In Barth syndrome, the TAZPOWER extension reported a six-minute walk change of 37.3 m, in those same 8 patients.

The full development arc is on the SS-31 complete guide.

What a buyer can actually verify

A research vial of SS-31 is not Forzinity. Same molecule name, different supply chain, no label, no pharmacy, no batch release by a regulator. The approved product's price has been reported in the $300,000 to $750,000 range per year, which tells you how far apart the two things are.

People also confuse SS-31 with MOTS-c, the other mitochondrial peptide in this market. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. Kumagai and colleagues showed in iScience in 2024 that it binds and activates CK2 in skeletal muscle, and Lu and colleagues reported a Bcl-2 interaction in liver disease in Cell Reports. Both are preclinical. Its human trial count is zero. The side-by-side is on the SS-31 vs MOTS-c page.

What to know now

What we're watching

Elamipretide (SS-31) and Barth syndrome: what the FDA actually approved

Frequently asked questions

Does SS-31 have any proven benefit?

One. The FDA approved elamipretide in September 2025 for Barth syndrome in patients weighing 30 kg or more, based on the TAZPOWER program. Long-term follow-up covers 8 patients over 168 weeks. No other benefit has an approval behind it.

Is SS-31 an anti-aging drug?

No human trial has tested it for aging. The strongest aging data is Mitchell et al., Aging Cell 2025, in mice. Cardiac and skeletal muscle function improved, but the paper reports no detectable change in tissue epigenetic or transcriptomic age.

Does SS-31 help fatigue or exercise capacity?

That exact question was tested. MMPOWER-3, reported by Karaa and colleagues in Neurology in 2023, did not meet its primary endpoints of six-minute walk distance or total fatigue score at 24 weeks in primary mitochondrial myopathy.

Is research-grade SS-31 the same as Forzinity?

It is the same molecule name, not the same product. Forzinity is a regulated prescription drug with a label and a reported annual cost in the $300,000 to $750,000 range. A research vial has no label, no approved use, and no regulatory batch release.

What did the genotype post hoc analysis show?

The 2024 Orphanet Journal of Rare Diseases re-analysis of MMPOWER-3 split patients by genotype and reported walk-distance differences in some subgroups, including figures of 25.2 m versus 2.0 m. Post hoc subgroup results are hypothesis-generating and do not overturn a missed primary endpoint.

References

  1. Shirley, M. (2025). Elamipretide: First Approval. Drugs, 86(3), 377–383. https://doi.org/10.1007/s40265-025-02269-8
  2. Stealth BioTherapeutics. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine. https://doi.org/10.1016/j.gim.2024.101138
  3. Karaa, A., Haas, R., Goldstein, A., Vockley, J., & Cohen, B. (2023). Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: The MMPOWER-3 randomized clinical trial. Neurology. https://doi.org/10.1212/WNL.0000000000207402
  4. Karaa, A., Bertini, E., Carelli, V., et al. (2024). Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: A post hoc analysis of the MMPOWER-3 trial. Orphanet Journal of Rare Diseases, 19(1), 431. https://doi.org/10.1186/s13023-024-03421-5
  5. Mitchell, W., Pharaoh, G., Tyshkovskiy, A., et al. (2025). The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell, 24(6), e70026. https://doi.org/10.1111/acel.70026
  6. Tung, C., Varzideh, F., Farroni, E., et al. (2025). Elamipretide: A review of its structure, mechanism of action, and therapeutic potential. International Journal of Molecular Sciences, 26(3), 944. https://doi.org/10.3390/ijms26030944
  7. Obi, C., Smith, A. T., Hughes, G. J., & Adeboye, A. A. (2022). Targeting mitochondrial dysfunction with elamipretide. Heart Failure Reviews, 27(5), 1925–1932. https://doi.org/10.1007/s10741-021-10199-2
  8. Clarke, S. L. N., Bowron, A., Gonzalez, I. L., et al. (2013). Barth syndrome. Orphanet Journal of Rare Diseases, 8, 23. https://doi.org/10.1186/1750-1172-8-23
  9. Gandhi, S., Sweeney, H. L., Hart, C. C., Han, R., & Perry, C. G. R. (2024). Cardiomyopathy in Duchenne muscular dystrophy and the potential for mitochondrial therapeutics to improve treatment response. Cells, 13(14), 1168. https://doi.org/10.3390/cells13141168
  10. Nashine, S. (2021). Potential therapeutic candidates for age-related macular degeneration (AMD). Cells, 10(9), 2483. https://doi.org/10.3390/cells10092483
  11. Rowe, L. W., Akotoye, C., Harris, A., & Ciulla, T. A. (2025). Beyond the injection: Delivery systems reshaping retinal disease management. Expert Opinion on Pharmacotherapy, 26(8), 939–952. https://doi.org/10.1080/14656566.2025.2496424
  12. Kumagai, H., Kim, S. J., Miller, B., et al. (2024). MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience, 27(11), 111212. https://doi.org/10.1016/j.isci.2024.111212
  13. Lu, H., Fan, L., Zhang, W., et al. (2024). The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. Cell Reports, 43(1), 113587. https://doi.org/10.1016/j.celrep.2023.113587

every peptide, every supplier question, one library.